Study Comparing Two Antibiotics for Resistant Infections
Part of Infections, Lungs & breathing clinical trials.
This study looks at two strong antibiotics, polymyxin B and colistin, given through a vein to treat serious infections like pneumonia or blood infections caused by bacteria that are resistant to many other antibiotics. The goal is to see how well they work and how safe they are.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have a serious infection caused by bacteria that are resistant to carbapenem antibiotics, like pneumonia, a blood infection, or another infection (not a urinary tract infection).
- You have already received polymyxin B or colistin through a vein for at least 3 days.
- You started treatment with polymyxin B or colistin within 7 days of the infection starting.
- You do not have a urinary tract infection that spread to your blood.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a new antibiotic (BV100 plus low-dose polymyxin B) against a standard treatment for pneumonia caused by a hard-to-treat bacteria (Acinetobacter baumannii). If you have hospital-acquired or ventilator-associated pneumonia and standard antibiotics aren't working, this study may offer a new option.
This study tests different antibiotic combinations for severe infections caused by hard-to-treat Gram-negative bacteria (like Pseudomonas or Acinetobacter). The goal is to find the best treatment for bloodstream infections or pneumonia that started in the hospital.
This trial studies whether cefiderocol plus ampicillin-sulbactam works better than colistin (sometimes with meropenem) for serious infections caused by carbapenem-resistant Acinetobacter baumannii (a hard-to-treat germ). It may help by finding a more effective antibiotic plan for people with these severe hospital-acquired infections.
This study compares an experimental antibiotic called ASK0912 with an approved antibiotic (polymyxin B) in adults with hospital-acquired or ventilator-associated pneumonia. It aims to see if the new drug is as effective and safe as the standard treatment.
This trial tests a combination of two antibiotics (meropenem and pralurbactam) for treating serious infections caused by bacteria that are resistant to many other antibiotics. It may be an option for hospitalized patients with pneumonia, urinary tract infections, abdominal infections, or bloodstream infections.
This study tests which of two antibiotic combinations works better at clearing infections caused by multi-drug-resistant bacteria in adults, including those with weakened immune systems. It aims to find a more effective treatment option.
Hear when a new Bacteremia Caused by Gram-Negative Bacteria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.